Company Description
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.
The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone.
It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.
In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications.
Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Frank Heuszel |
Contact Details
Address: 1400 Broadfield Blvd., Suite 130 Houston, Texas 77084 United States | |
| Phone | 585-325-3610 |
| Website | impactbiomedinc.com |
Stock Details
| Ticker Symbol | IBO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $3.00 |
| CIK Code | 0001834105 |
| Employer ID | 85-3926944 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Frank D. Heuszel Esq., J.D. | Chairman and Chief Executive Officer |
| Todd D. Macko CPA | Chief Financial Officer. Secretary and Treasurer |
| Mark J. Suseck | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 8, 2024 | 8-K | Current Report |
| Sep 17, 2024 | 8-K | Current Report |
| Sep 17, 2024 | 424B4 | Prospectus |
| Sep 13, 2024 | EFFECT | Notice of Effectiveness |
| Aug 27, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 23, 2024 | 8-A12B/A | Filing |
| Aug 20, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 13, 2024 | 10-Q | Quarterly Report |